Discussions surrounding the potential rise of cognitive enhancers dubbed Brain Ozempic highlight fears of a dystopian corporate landscape where neural implants and pills are used to maximize employee productivity. Readers compare these hypothetical advancements to existing ADHD medications, noting how current treatments already blur the lines between therapeutic relief for executive dysfunction and recreational focus. Ultimately, the debate underscores growing concerns over whether future neurotechnologies will serve as medical game-changers or tools for extreme corporate exploitation.